• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA clears Transseptal Solutions’ TP Crosser transseptal access device

FDA clears Transseptal Solutions’ TP Crosser transseptal access device

October 12, 2018 By Fink Densford

Transseptal Solutions

Medtech developer Transseptal Solutions said yesterday it won FDA 510(k) clearance for its TSP Crosser transseptal access system.

The Israel-based company said that the TSP Crosser is an advanced transseptal puncture system which features a built-in steering mechanism and is designed for use in accessing the left atrium.

The system is intended for use during procedures including mitral valve repair and replacement, paravalvular leak closure, left atrial appendage closure and EP ablation treatments.

“Transseptal Solutions FDA clearance announcement is timely. There is a growing global demand for trans-septal catheter intervention for patients with structural heart disease. The TSP Crosser is an innovative integrated solution addressing the unmet need for precise and controlled transseptal puncture,” founder Francesco Maisano of Zurich University Hospital said in a prepared statement.

The newly cleared system combines a sheath, dilator and flexible puncturing needle for left atrium access and transseptal catheterization procedures. The device’s loop wire is radiopaque and positioned at the distal end of the steerable sheath to aid in localization of the fossa ovalis, Transseptal Solutions said.

“Transseptal catheterization is a critical step for structural heart and electrophysiology LA interventions. The availability of advanced tools and techniques is essential to perform accurate transseptal puncture as part of challenging LA interventions. The TSP Crosser is designed to provide controlled access and stable catheter positioning into the heart’s left atrium. An innovative radiopaque loop wire aids in the localization of the fossa ovalis within the right atrium and provides device stability during an interatrial septum puncture. Moreover, the flexible puncturing needle allows deflection and orientation using the steerable sheath to provide adjustable positioning for puncturing the fossa ovalis and ensuring the TSP Crosser™ successfully reaches its target location within the LA anatomy,” CEO Elad Sapir said in a press release.

The company said that it has already won CE Mark approval in the European Union for the device.

Filed Under: 510(k), Cardiovascular, Catheters, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: transseptalsolutions

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy